HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

References

• Rosell R, González-Cao M. Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer. Lancet. 2021;397(10274):557–559. doi:10.1016/S0140-6736(21)00196-3
   PubMed Web of Science ®Google Scholar
• González-Cao M, Morán T, Dalmau J, et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the Phase 2 DURVAST Study. JAMA Oncol. 2020;6(7):1063–1067. doi:10.1001/jamaoncol.2020.0465
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Gonçalves PH, Abdul-Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a Phase 1 study. JAMA Oncol. 2019;5(9):1332–1339. doi:10.1001/jamaoncol.2019.2244
   PubMed Web of Science ®Google Scholar
• Hanna NH, Schneider BJ, Temin S, et al. Therapy for Stage IV non–small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2020;38(14):1608–1632. doi:10.1200/JCO.19.03022
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):75. doi:10.1186/s40425-018-0382-2
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Litchfield K, Reading JL, Puttick C, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596–614.e514. doi:10.1016/j.cell.2021.01.002
   PubMed Web of Science ®Google Scholar
• Booth DS, Cheng Y, Frankel AD. The export receptor Crm1 forms a dimer to promote nuclear export of HIV RNA. Elife. 2014;3:e04121. doi:10.7554/eLife.04121
   PubMed Web of Science ®Google Scholar
• Gupta A, Saltarski JM, White MA, Scaglioni PP, Gerber DE. Therapeutic targeting of nuclear export inhibition in lung cancer. J Thorac Oncol. 2017;12(9):1446–1450. doi:10.1016/j.jtho.2017.06.013
   PubMed Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi:10.1056/NEJMoa1903455
   PubMed Web of Science ®Google Scholar
• Farren MR, Hennessey RC, Shakya R, et al. The exportin-1 inhibitor selinexor exerts superior antitumor activity when combined with t-cell checkpoint inhibitors. Mol Cancer Ther. 2017;16(3):417–427. doi:10.1158/1535-7163.MCT-16-0498
   PubMed Web of Science ®Google Scholar
• Sun H, Hattori N, Chien W, et al. KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer. 2014;111(2):281–291. doi:10.1038/bjc.2014.260
   PubMed Web of Science ®Google Scholar
• Bracht JWP, Gimenez-Capitan A, Huang CY, et al. Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform. Sci Rep. 2021;11(1):3712. doi:10.1038/s41598-021-83132-0
   PubMed Web of Science ®Google Scholar
• Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–895. doi:10.1016/j.annonc.2021.04.008
   PubMed Web of Science ®Google Scholar
• Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: checkMate 9LA 2-year update. ESMO Open. 2021;6(5):100273. doi:10.1016/j.esmoop.2021.100273
   PubMed Web of Science ®Google Scholar
• Scharpf RB, Balan A, Ricciuti B, et al. Genomic landscapes and hallmarks of mutant RAS in human cancers. Cancer Res. 2022;82(21):4058–4078. doi:10.1158/0008-5472.CAN-22-1731
   PubMed Web of Science ®Google Scholar
• Qiao M, Jiang T, Liu X, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn? J Thorac Oncol. 2021;16(8):1267–1288. doi:10.1016/j.jtho.2021.04.003
   PubMed Web of Science ®Google Scholar
• Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, Phase 3 trial. Lancet Oncol. 2022;23(9):1167–1179. doi:10.1016/S1470-2045(22)00382-5
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Vasquez KM. Targeting chromosomal architectural HMGB proteins could be the next frontier in cancer therapy. Cancer Res. 2020;80(11):2075–2082. doi:10.1158/0008-5472.CAN-19-3066
   PubMed Web of Science ®Google Scholar
• Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38:40–48. doi:10.1016/j.smim.2018.02.011
   PubMed Web of Science ®Google Scholar
• Tripathi A, Pandey V, Sahu AN, Singh A, Dubey PK. Di-(2-ethylhexyl) phthalate (DEHP) inhibits steroidogenesis and induces mitochondria-ROS mediated apoptosis in rat ovarian granulosa cells. Toxicol Res. 2019;8(3):381–394. doi:10.1039/C8TX00263K
   Web of Science ®Google Scholar
• Tcyganov EN, Sanseviero E, Marvel D, et al. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell. 2022;40(10):1173–1189.e1176. doi:10.1016/j.ccell.2022.09.001
   PubMed Web of Science ®Google Scholar
• Singh K, Lin J, Lecomte N, et al. Targeting eIF4A-dependent translation of KRAS signaling molecules. Cancer Res. 2021;81(8):2002–2014. doi:10.1158/0008-5472.CAN-20-2929
   PubMed Web of Science ®Google Scholar
• Amato J, Madanayake TW, Iaccarino N, et al. HMGB1 binds to the KRAS promoter G-quadruplex: a new player in oncogene transcriptional regulation? Chem Commun. 2018;54(68):9442–9445. doi:10.1039/C8CC03614D
   PubMed Web of Science ®Google Scholar
• Deng J, Thennavan A, Dolgalev I, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. Nat Cancer. 2021;2(5):503–514. doi:10.1038/s43018-021-00208-6
   PubMedGoogle Scholar
• Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–842. doi:10.1038/ni.2376
   PubMed Web of Science ®Google Scholar
• Wang W, Chapman NM, Zhang B, et al. Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-κB contributes to UV radiation-induced immune suppression. Cancer Res. 2019;79(11):2909–2922. doi:10.1158/0008-5472.CAN-18-3134
   PubMed Web of Science ®Google Scholar
• Ming M, Wu W, Xie B, et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of IkappaB. Mol Cancer Ther. 2018;17(12):2564–2574. doi:10.1158/1535-7163.MCT-17-0789-ATR
   PubMed Web of Science ®Google Scholar
• Saenz-Ponce N, Pillay R, de Long LM, et al. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Sci Transl Med. 2018;10(447). doi:10.1126/scitranslmed.aar7223
   PubMed Web of Science ®Google Scholar